Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2M | P61081 | 2/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417356 | 0.96 | DRD2 (0.46) | UBE2MDCUN1D1SIGMAR1DRD4TACR1 | |
| SCHEMBL6417889 | 0.85 | UBE2M (0.47) | UBE2MDCUN1D1SIGMAR1SLC6A5MEN1 | |
| SCHEMBL6417353 | 0.81 | DRD2 (0.47) | UBE2MDCUN1D1SIGMAR1MEN1KMT2A | |
| SCHEMBL6410694 | 0.80 | TSHR (0.58) | — | |
| SCHEMBL6410223 | 0.77 | ALDH1A1 (0.42) | — | |
| SCHEMBL6411735 | 0.75 | KCNA5 (0.43) | TACR1 | |
| SCHEMBL6413424 | 0.75 | MAPT (0.46) | MEN1KMT2A | |
| SCHEMBL6411908 | 0.74 | KCNA5 (0.43) | TACR1 | |
| SCHEMBL6413218 | 0.74 | HSD17B10 (0.47) | — | |
| SCHEMBL6416804 | 0.73 | TACR1 (0.34) | MEN1KMT2ATACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | claimed |
| WO-2004004727-A1 | 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | AXYS PHARMACEUTICALS, INC. (US) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124614-A1 | 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis | CASP3, BAX, BAD | UBE2M 2997/4885DCUN1D1 901/4885SIGMAR1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.